10-K: AccuStem Sciences Reports 2025 Financials, Faces Going Concern Doubt

AccuStem Sciences, Inc. filed its annual report for the fiscal year ended December 31, 2025, detailing continued net losses and significant cash burn, raising substantial doubt about its ability to continue as a going concern.

Summary

• AccuStem Sciences, Inc. reported its annual results for the fiscal year ended December 31, 2025.
• The company incurred a net loss of $1,756,096 for the year, an increase from $1,505,102 in the prior year.
• As of December 31, 2025, the company had an accumulated deficit of $9,783,143.
• The company's cash balance at year-end was $13,929, which is insufficient to fund operations beyond January 2026.
• Management acknowledges substantial doubt about the company's ability to continue as a going concern.
• The company is actively pursuing additional equity financing to fund its operations and development activities.
• Research and development expenses increased by 103% to $281,014, primarily due to technology transfer activities.
• General and administrative expenses rose by 8% to $1,475,082, attributed to increased public relations, travel, and professional fees.
• The company plans to launch its MSC and StemPrintER genomic tests in the US, with a target market opportunity estimated at over $6.3 billion annually.
• Key milestones for commercialization include establishing a CLIA-certified laboratory partner, which is expected to take approximately 6 months.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the significant net loss, critically low cash reserves, and the explicit mention of substantial doubt regarding the company's ability to continue as a going concern, despite ongoing efforts to secure financing.

Positives

• Research and development expenses increased, indicating continued investment in product development.
• The company has partnered with EmeritusDx for laboratory services, a step towards commercialization.
• The company is actively pursuing equity financing to address its liquidity needs.
• The company has a clear plan to launch its MSC and StemPrintER tests, targeting a significant market opportunity.

Negatives

• The company incurred a net loss of $1,756,096 for the fiscal year ended December 31, 2025.
• The company has an accumulated deficit of $9,783,143 as of December 31, 2025.
• Cash and cash equivalents were only $13,929 at year-end, insufficient to fund operations beyond January 2026.
• Management has identified substantial doubt about the company's ability to continue as a going concern.
• The company has not generated any revenue to date.
• Research and development expenses increased significantly, indicating ongoing investment without corresponding revenue.
• General and administrative expenses also increased, adding to the operational costs.

Risks

• The company has incurred net losses in every year since inception and anticipates continuing losses, with no guarantee of achieving profitability.
• Substantial additional funding is required to complete product development, and this funding may not be available on acceptable terms.
• Recurring losses from operations raise substantial doubt about the company's ability to continue as a going concern.
• The company's rights to develop and commercialize product candidates are subject to license agreements, and failure to comply could result in loss of license rights.
• Failure to obtain and maintain patent protection could allow competitors to develop similar products.
• There is no guarantee that the company will be able to demonstrate the clinical utility of MSC and StemPrintER, which is crucial for reimbursement and commercialization.
• The company is dependent on third parties for certain resources and services.
• The company faces risks associated with medical and technological change and obsolescence.
• The market opportunities for product candidates may be smaller than anticipated.
• The commercial success of product candidates depends on market acceptance by physicians, patients, and third-party payors.
• Failure to obtain or maintain adequate insurance coverage at an acceptable cost could adversely affect the business.
• The company's limited accounting resources have resulted in a material weakness in internal controls over financial reporting.
• The company's common stock trading on OTC Markets can be volatile and sporadic.

Future Outlook

The company anticipates continued operating losses and expects to incur substantial additional expenditures to support its planned activities, including establishing a CLIA certified laboratory. Funding for these activities and future commercialization depends on raising additional capital through equity financings, debt financings, or strategic transactions. The company's ability to fund its operations and development is uncertain.

Management Comments

• Management believes that the Company does not have sufficient cash and current assets to support its operations through at least 12 months from the issuance date of these consolidated financial statements, and will require significant additional cash resources to continue its planned research and development activities.
• Management has determined that the control deficiencies constitute a material weakness in internal control over financial reporting due to a lack of accounting resources.
• Management intends to remediate this item by recruiting appropriately skilled accounting resources.

Industry Context

StockSavvy.ai notes that AccuStem Sciences operates in the competitive clinical stage diagnostics sector, focusing on oncology. The company's strategy to develop and commercialize genomic tests like MSC for lung nodules and StemPrintER for breast cancer aligns with industry trends towards personalized medicine and improved diagnostic accuracy. However, the company faces significant challenges related to funding, regulatory hurdles, and market adoption, common in this high-risk, high-reward industry.

Comparison to Industry Standards

• The company's net loss of $1,756,096 for the year and accumulated deficit of $9,783,143 are substantial for a company at its stage, highlighting the capital-intensive nature of diagnostic test development.
• The company's cash balance of $13,929 is critically low, indicating a significant need for immediate financing, which is a common challenge for early-stage biotech and diagnostics firms.
• The increase in R&D expenses by 103% reflects the typical investment required for clinical validation and regulatory pathway progression in the diagnostics industry.
• The identified material weakness in internal controls due to a lack of accounting resources is a concern, though not uncommon for rapidly growing or early-stage companies that may not have fully developed financial infrastructure.

Related Party Transactions

• The company has a shared services agreement with Tiziana Life Sciences plc for limited management and administrative services, with costs based on actual time spent and allocated payroll costs.
• The company is charged at cost for office space utilization from Tiziana Life Sciences plc.
• As of December 31, 2025, there was a balance due to Tiziana Life Sciences plc for shared services ($94,621), expenses paid on behalf of the company ($198,424), and funding support ($3,351,500).
• Gabriele Cerrone, Chairman of the Board, provides consulting services for a monthly fee of $5,500, with $49,500 due as of December 31, 2025.
• Unpaid fees for Mr. Cerrone were settled with shares in March 2025 (121,732 shares for $27,000) and November 2024 (754,000 shares for $187,500).
• Amounts due to John Brancaccio for unpaid director fees were $162,500 as of December 31, 2025.
• Amounts due to Sean Macdonald for unpaid director fees were $158,333 as of December 31, 2025.
• Amounts due to Willy Simon for unpaid director fees were $159,194 as of December 31, 2025.
• Amounts due to Keeren Shah for unpaid consultancy fees were $41,282 as of December 31, 2025.
• Amounts due to Jeff Fensterer for unpaid expenses were $7,485 as of December 31, 2025.

Stakeholder Impact

• Shareholders may experience dilution if the company issues additional shares to raise capital.
• The company's ability to continue as a going concern poses a significant risk to shareholders.
• Employees may be impacted by the company's financial instability and potential need for restructuring or further funding rounds.
• Suppliers and partners may face payment delays or uncertainty due to the company's liquidity constraints.

Next Steps

• Secure additional equity financing to fund operations and development.
• Complete key milestones for commercialization, including establishing a CLIA-certified laboratory partner.
• Transfer MSC and StemPrintER assays to the laboratory partner.
• Seek U.S. Clinical Laboratory Improvement Amendments of 1988 (CLIA) certification.
• Seek reimbursement from the Centers for Medicare and Medicaid Services (CMS).
• Launch MSC and StemPrintER tests in the US.
• Expand to other markets as clinical need and revenue opportunities are evaluated.
• Remediate material weakness in internal controls by recruiting skilled accounting resources.

Key Dates

Recommendation

The company's dire financial situation, characterized by significant losses, a critical cash shortage, and a going concern warning, coupled with the lack of revenue and reliance on future financing, presents a high-risk investment profile. While the technology has potential, the immediate financial viability is in question, making it a speculative investment with a high probability of failure without substantial capital infusion on favorable terms.

Keywords

AccuStem Sciences, Form 10-K, Annual Report, Diagnostics, Oncology, MSC, StemPrintER, Lung Nodules, Breast Cancer, Genomic Tests, Clinical Stage, Net Loss, Going Concern, Financing